• VDR Links Oxidative Stress to Salivary Ferroptosis

  2026-08-11

  The reference study identifies vitamin D receptor upregulation as a sex-specific regulator connecting systemic oxidative stress, transferrin receptor expression, and ferroptosis-related salivary hyposecretion in Sod1-knockout female mice. Its combined mouse and cell-model design provides a mechanistic framework for studying dry mouth associated with oxidative injury while highlighting the need for pharmacological validation of ferroptosis as a therapeutic target.

• Tivozanib (AV-951) in Reliable Cell Assays

  2026-08-10

  A scenario-based guide to using Tivozanib (AV-951), SKU A2251, in cell viability, proliferation, and cytotoxicity workflows. It connects assay interpretation, compound handling, protocol design, data comparison, and vendor selection to practical laboratory decisions.

• α-Amanitin Workflow for RNA Polymerase II Studies

  2026-08-09

  Use α-Amanitin as a controlled transcriptional perturbation tool for RNA polymerase function assays, gene expression pathway analysis, and developmental models. This workflow emphasizes dose-aware design, transcription-versus-ribosome interpretation, and practical troubleshooting for cell and embryo experiments.

• EDI3 Inhibition in HER2-Therapy-Resistant Breast Cancer

  2026-08-08

  Keller et al. identify the glycerophosphodiesterase EDI3/GPCPD1 as a HER2-regulated metabolic vulnerability in ER−HER2+ breast cancer, including models resistant to HER2-targeted therapy. By combining patient samples, mechanistic cell studies, gene silencing, pharmacological inhibition, and xenografts, the study supports EDI3 as a candidate target while highlighting important limits for clinical translation.

• PD 173074: Translating FGFR Biology in Pancreatic Cancer

  2026-08-07

  A translational framework for using PD 173074 to connect FGFR1 and VEGFR2 biology with pancreatic cancer risk modeling, mechanistic validation, and disciplined experimental design.

• Nintedanib (BIBF 1120) in ATRX-Deficient Glioma: Protocols &

  2026-08-07

  Nintedanib (BIBF 1120) stands out as a triple angiokinase inhibitor with pronounced efficacy in ATRX-deficient glioma models, where it exploits unique vulnerabilities in the angiogenesis pathway. This article delivers optimized protocols and troubleshooting strategies, translating breakthrough findings into actionable steps for cancer and fibrosis research teams.

• Applied mCherry mRNA: Optimizing Red Fluorescent Protein Ass

  2026-08-06

  EZ Cap™ mCherry mRNA (5mCTP, ψUTP) empowers robust, immune-evasive red fluorescent protein reporter workflows. Discover step-by-step enhancements, troubleshooting strategies, and novel insights from kidney-targeted mRNA nanoparticle research that directly inform cell-based assay design.

• Optimizing Cell Assays with 5,6-Dichloro-1-β-D-ribofuranosyl

  2026-08-06

  This article addresses real laboratory challenges in cell viability, proliferation, and cytotoxicity assays, highlighting how 5,6-dichloro-1-β-D-ribofuranosyl-1H-benzimidazole (DRB, SKU C4798) improves reproducibility and interpretability in transcriptional inhibition workflows. Evidence-backed Q&A scenarios guide researchers on protocol optimization, data interpretation, and vendor selection, establishing DRB as the preferred CDK inhibitor for robust RNA polymerase II inhibition.

• Gramine Induces Ferroptosis via CUL3–MTDH Axis in TNBC Model

  2026-08-05

  This study identifies Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) as a direct inducer of ferroptosis in triple-negative breast cancer (TNBC) cells through modulation of the CUL3–MTDH ubiquitination axis. The findings provide mechanistic insight and practical direction for using Gramine in cancer biology research targeting ferroptosis and ubiquitination pathways.

• PF-562271 HCl: Translating FAK/Pyk2 Inhibition into Precisio

  2026-08-05

  Explore how PF-562271 HCl, a potent FAK/Pyk2 inhibitor, enables precision cancer research by modulating focal adhesion kinase signaling. This article uniquely bridges molecular inhibition to advanced predictive strategies in tumor biology.

• VE-822 ATR Inhibitor: Precision DNA Damage Response Control

  2026-08-04

  VE-822 stands out as a potent ATR inhibitor, enabling precise modulation of DNA damage response, especially for sensitizing pancreatic cancer models to chemoradiotherapy. This guide translates the latest nuclear cGAS research and real-world workflows into practical protocols, troubleshooting strategies, and advanced use-cases, empowering oncology labs with actionable, reproducible results.

• Improving In Vitro Drug Response Assessment in Cancer Resear

  2026-08-04

  Schwartz’s dissertation introduces a critical distinction between relative and fractional viability in in vitro drug response assays, revealing that most anti-cancer agents impact both proliferation and cell death with variable timing and proportion. This nuanced understanding facilitates more accurate evaluation of compounds like Pazopanib Hydrochloride in translational oncology workflows.

• Dual SMAD and Wnt Inhibition Enables Efficient iPSC-to-RGC D

  2026-08-03

  This study introduces a chemically defined protocol leveraging dual SMAD and Wnt inhibition to reproducibly differentiate human induced pluripotent stem cells (iPSCs) into retinal ganglion cells (RGCs) with high purity. The method addresses longstanding challenges of variability and yield, providing a robust foundation for disease modeling and regenerative research in optic neuropathies.

• Overcoming Sunitinib Resistance in ccRCC: Mechanistic and St

  2026-08-03

  This thought-leadership article explores the mechanistic underpinnings and translational strategies for overcoming sunitinib resistance in clear cell renal cell carcinoma (ccRCC). By integrating recent findings on TRIB3-mediated ferroptosis, expert protocol guidance, and a landscape analysis, it delivers actionable insights to translational researchers seeking to maximize the impact of multi-targeted receptor tyrosine kinase inhibitors in oncology.

• AAL-993: Next-Generation VEGF Receptor Inhibitor in Tumor An

  2026-08-02

  Explore how AAL-993, a potent VEGF receptor inhibitor, is revolutionizing tumor angiogenesis research with unparalleled selectivity and translational potential. This in-depth analysis highlights novel mechanistic insights and practical protocol strategies that set it apart from existing guides.

14679 records 1/979 page Next 12345 下5页 Last page